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Introduction
Due to widespread use of cross sectional imaging, 
incidence of overall neuroendocrine tumour including 
pancreatic neuroendocrine tumour (PNET) have increased 
substantially (1,2). PNET are rare and generally slow 
growing. They represent 3% of all pancreas neoplasms (3). 
At least 50% of PNETs are non-functioning and hence 
asymptomatic. As a result, PNETs are commonly an 
incidental finding diagnosed from imaging for other 
complaints. Due to the recent widespread use of high-
resolution radiological and endoscopic imaging techniques, 
there is a dramatic rise in the incidence of such tumours. 
Most PNETs are sporadic in nature. Risk factors include 
smoking, a high body mass index, and a positive family 
history which accounts for a variable percentage of patients 
with inherited syndromes such as multiple endocrine 
neoplasia type 1 (MEN1). Prognosis of PNETs depends 
on clinico-pathological factors including tumour size, 
differentiation and proliferative index which give an 
indication of the biological aggressiveness of the tumour 
and likelihood of lymph node involvement (4-6). 
Although several guidelines exist to guide the treatment 
of functioning and non-functioning PNETs (7,8). It is 
generally accepted that tumours >2 cm and functioning 
tumours should be resected but the management of non-
functioning tumours <2 cm remains controversial. Further 
controversy exists as to the approach of resection (open vs. 
laparoscopic) and the management of PNETs with liver 
metastasis which occurs in up to 80% of patients. The aim 
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of this paper is to review the current evidence of surgical 
resection in PNETs, the role of laparoscopic surgery and 
the management of liver metastasis.
Surgery vs. active surveillance
In general, it is recommended that PNET which is 
symptomic, functional, size ≥2 cm or with presence of 
aggressive features like pancreatic duct dilation should 
undergo pancreatic resection (9,10). However, it is 
controversial whether surgery should be recommended 
for PNET ≤2 cm as primary treatment. Some surgeons 
recommended upfront surgery, while other guidelines 
recommended active surveillance for asymptotic small 
PNET (7,11). Most less than 2 cm PNET were likely in 
benign and indeterminate risk in malignancy. Only 6% of 
incidental found smaller than 2 cm non-functioning PNET 
is confirmed to be malignancy (12). Small PNET (<2 cm) 
were slowing growing with indolent course, it is considered 
to be amenable to observation (12-14). 
Jung et al. reported a retrospective cohort of 145 
patients with NET ≤2 cm, in which 85 patients undergoing 
active surveillance (15). After years of clinical and 1 year 
of radiological follow up, 82% of patients under active 
surveillance did not find any change in size of tumor. Sadot 
et al. reported a case-matched comparative study between 
observation and surgery on patients with treatment naive 
PNET ≤3 cm (16). While patients in observation was older 
and tended to be shorter in follow up (44 vs. 57 months, 
P=0.06), median size did not change and no patients in 
either group was died from the disease at the end of study. 
Five-year metastasis free survival was comparable between 
observation and resection (99% vs. 88%, P=0.08). Sallinen 
et al. reported a meta-analysis on surveillance strategy for 
small asymptotic non-functional PNET (17). It included 9 
articles with 344 patients with sporadic and 64 patients with 
MEN1 related non-functional PNET. Majority of patients 
who selected for active surveillance were having small tumor 
with tumor size less than 2 and low grade. Some study even 
considered tumor size ≥4 cm for active surveillance (13). 
After mean duration of follow up ranged from 32 to 
45 months, no patients developed lymph node and distant 
metastasis. Pool estimate of 22% (range, 0–51%) patients 
have a growing tumor on follow up. A growth rate of 
0.12 mm 1.5%±5.5% per year was reported (14). In another 
systemic review on active surveillance for 327 patients with 
sporadic, asymptotic small non-functioning PNET, no 
disease-specific death was reported during the follow up (18). 
No distant metastasis was found in PNET ≤2 cm. In one 
retrospective reported by Rosenberg et al., three patients 
developed distant metastasis after surveillance for median 
follow up of 28 months. However, all three patients had 
the tumor larger than 2 cm (19). Under active surveillance, 
about 14.1% of patients proceed for pancreatic resection 
after median follow up of 28–45 months. About 3–14% 
tumor noted to have increased in size for more than 20% on 
follow up (14,15). Increasing tumor size, and patient choice 
were the main reason of surgery. Other reasons of failure in 
continuous observation included appearance of symptoms 
and pancreatic duct dilation (18). 
Other than indolent natural history of small PNET, 
surgical morbidity is the other reason advocating active 
surveillance. Pancreatic surgery is considered as high-risk 
in morbidity and mortality. Even though post-operative 
mortality has been reported to be low and around 1% in 
high-volume center, it increased up to 10% in nationwide 
study (20,21). It is especially true for tumor locating at the 
head of pancreas requiring pancreatioduodenectomy. In 
consideration of management strategy, age, comorbidity, 
natural history of tumor, morbidity and mortality of 
treatment have to be taken into account. Therefore, 
European Neuroendocrine Tumor Society (ENETS) 
guideline recommended a “wait and see” policy as for PNET 
<2 cm. Active surveillance with six-monthly and then yearly 
follow up with imaging were recommended (7,22). 
However, there were limitations with the current 
evidence supporting active surveillance. As PNET is a slow-
growing tumor, studies with follow-up up to 3 to 4 years 
cannot reflect the long-term prognosis. It is important in 
stratifying patients for surgical interventions, especially 
young individuals who had found a small PNET. Young 
patients are likely to live long but have to cope with the 
stress and the presence of the disease. As the majority of 
reasons for pancreatic resection is tumor growth, there is 
a cumulative need for operation in long-term follow up. 
On the other hand, nearly all studies were retrospective in 
nature. They did not state the criteria in selecting surgery 
or observation. The treatment decision was based on 
patients’ age, pre-morbid conditions and patients’ decision. 
It was reflected by the fact that patients in observation were 
usually older (13,16).
In contrary to retrospective comparative studies 
supporting active surveillance, registry studies based on 
nationwide database reported contradictory results. Sharpe 
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et al. evaluated 380 patients with ≤2 cm PNET from the US 
National Cancer Data Base (NCDB) from 1998 to 2006 (23). 
Patients undergoing observation were likely to be older and 
receiving non-surgical therapy. Five-year overall survival 
was less than those undergoing surgical treatment (34.3% 
vs. 82.2%, P<0.0001). After controlling the cofounding 
factors, observation, poorly differentiated histology, lymph 
node positivity, and nonsurgical therapies were associated 
with increased mortality. Expectant management had a 
2.8-fold risk of having death on follow up. Another study 
by Gratian et al. reported a similar finding. A longer period 
[1998–2011] and number of patients (1,854 patients) 
were retrieved from NCDB (24). To evaluate the effect of 
pancreatectomy, they included non-functional PNETs and 
non-specific neuroendocrine tumours. They also excluded 
those patients with unknown surgical status or type of 
surgery and those with more than one malignant primary 
tumor. In this study, 303 patients (16%) presented with 
regional metastasis and 180 (10%) patients presented with 
distant metastasis were included. Twenty-seven percent of 
patients who did not underwent surgery were older, more 
likely to have metastasis, poorly differentiated tumor and 
be treated in non-academic hospital. After excluding distant 
metastasis, not offering surgery because of comorbidity 
and death before surgery, unadjusted 5-year overall survival 
for patient with small PNET undergoing observation was 
27.6% and patients undergoing pancreatic resection was 
72.3–86.0%. There was no difference in overall survival 
between different types of operation. These two studies 
showed different conclusions with other retrospective 
studies. Several reasons could explain this finding. Firstly, 
patients were in the disease status between different studies, 
as cohort in NCDB study included patients with regional 
and distant metastasis. While we considered overall 
survival as the outcome measure, the effect of surgery 
could be overestimated as patients with lower stage and 
better performance status would be selected for operation. 
Secondly, the reasons on surveillance and surgery were 
not well reported in registry-based studies. The decisions 
between observation and surgery were multifactorial 
which included financial status, co-morbidity and access 
to medical service. It might lead to fundamental difference 
between patients on decision-making. Thirdly, patients with 
mild and less aggressive tumor were often underreported. 
More symptomic tumours with aggressive behavior, like 
pancreatic duct or bile duct dilation, should be undergoing 
surgical treatment. It is unsure if these patients were 
inappropriately chosen for observation.
Laparoscopic resection vs. open
Pancreatic surgery with minimally invasive technique was 
first described in 1990s. Cuschieri et al. described a report 
on laparoscopic distal pancreatectomy, while by Gagner et al. 
reported the first case on laparoscopic pylorus-preserving 
pancreatioduodenectomy (25,26). Since then, numbers of 
retrospective study have been reported with satisfactory 
outcome. Our group has reported one of the earliest 
series on laparoscopic resection of PNET. Four patients 
with insulinoma underwent laparoscopic surgery. Two 
enucleations and two distal pancreatectomies have been 
performed. Neither major complication nor conversion 
were reported (27). Zerbi et al. conducted a prospective 
multi-center study including 310 patients with PNET in 24 
Italian centers (28). While only 21 out of 262 patients (6%) 
were operated through laparoscopic approach. Majority 
of patient (18 cases) had their tumor at body or tail, and 
3 tutors were located at head. Majority of laparoscopic 
pancreatic surfer was successful with the need of conversion. 
Early reports on laparoscopic pancreatic resection reviewed 
conversion rate ranged from 9% to 41% (29). Deep 
adhesions, tumor deeply immersed in the parenchyma and 
inability to locate the tumor during laparoscopic procedure 
were the major reasons for conversion (30-32).
Comparing to conventional pancreatic resection, 
laparoscopic approach has showed comparable surgical 
outcome. Drymousis et al. reported a meta-analysis of 
906 patients with PNET comparing laparoscopic to 
conventional surgery (29). They found that laparoscopic 
resection had less blood loss (by 67 mL, P=0.008) and 
shorter length of stay (by 5 days, P≤0.00001). There 
was no significant difference in rate of pancreatic fistula, 
operative duration and mortality (29). Tamburrino recently 
conducted a meta-analysis and reported the similar findings. 
Comparing to open pancreatic surgery, shorter length of 
hospital stay (less 4.5 days, P<0.001) and less blood loss 
(less 66.84 unit, P=0.008) were found in laparoscopic group. 
There was no difference in duration of operation, overall 
postoperative complication, rate of pancreatic fistula, 
re-operation and post-operative mortality. In terms of 
oncological outcome, two studies have reported the rate 
of recurrence between laparoscopic and open pancreatic 
surgery (33,34). In the pooled analysis of two studies, there 
was 4.2% recurrence in patients undergoing laparoscopic 
surgery, while it was 9.3% in conventional surgery group. 
However, it is not statistically significant (odd ratio =0.46, 
P=0.15) (35).
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Due to rarity of the disease, majority of the reported 
study were retrospective with small sample size. Small 
low-grade tumours were more likely to be selected for 
laparoscopic surgery. Selection bias on surgical modality 
is not negligible. It is reflected by the fact that there was 
significant difference in age, sex and tumor size between 
laparoscopic arm and conventional surgical arm (27,28). 
Therefore, these results have to be interpreted cautiously. 
Despite the potential bias, these studies confirmed that 
laparoscopic resection is feasible and safe in patients with 
PNET. Further studies will be indicated to decide which 
patients and extent of disease would be best treated with 
laparoscopic approach. On the other hand, there were 
limited studies evaluating the oncological outcome after 
laparoscopic resection. Future randomized controlled trial 
will be worthwhile to explore the outcome. 
Management with liver metastasis 
Liver metastasis is very common in patients with NET. 
28.3–77% of patients with PNET develop liver metastasis 
during the course of their disease (36,37). In managing NET 
with liver metastasis, surgery helps in reducing tumor burden 
and hormonal secretion in functioning tumor (38,39). If 
liver metastasis is left untreated, 5-year survival was only 
30–40% (40,41). Improved survival has been reported if 
liver metastasis was resected, especially if complete resection 
was achieved. 5 years overall survival can be up to 60–80% 
(42-44). Glazer et al. reported a series of 172 patients with 
NET liver metastasis undergoing liver resection. Median 
overall survival was 9.6 years, while positive margin did 
not affect overall survival probability (44). Watzka et al. 
reported their series of 204 patients with hepatic metastasis 
of NET. In patients with R0 resection, 10-year survival was 
90.4% comparing to 53.4% and 51.4% in patients with 
R1 and R2 resection respectively. On the other hand, poor 
10-year overall survival of 19.4% was found in patients 
cannot undergo liver resection (45). Saxena et al. published 
a systemic review of 29 article in evaluating the efficacy 
of liver resection in NET liver metastasis (46). Five-year 
overall survival rate in patients undergoing liver resection 
was 70.5% (range, 31–100%) and 5-progression free survival 
was 29% (6–66%). Resection leaded to complete symptomic 
improvement in 73% of patients (23–92%). On other hand, 
despite incomplete resection, cytoreductive surgery placed 
a role not only in reducing the hormonal secretion but also 
survival benefits. Mayo et al. reported a multi-center study 
on surgical management of NET with liver metastasis. 
Forty percent of patients was having pancreatic NET as the 
primary site. Seventy-eight percent of patients underwent 
liver resection, 3% underwent ablation and 19% underwent 
both ablation and liver resection as the treatment. Despite 
94% of patients have disease recurred at 5 years, 5-year 
overall survival was 74%. Patients with synchronous disease, 
non-functional status and extra hepatic disease predicted 
worse survival outcome (47).
Patients with G1 or G2 PNET, functioning tumor, 
resectable liver metastasis, absence of extra-hepatic 
metastasis or Carcinoid Heart’s disease should consider 
liver resection as the primary treatment on NET with 
liver metastasis (7,22). In patients with unrespectable liver 
metastasis, debulking surgery should be limited to those 
with functional tumor or those refractory to other non-
surgical treatments. However, most studies reported the 
outcome of management of NET liver metastasis from 
different origins, including pancreas, colon, lung, thymus 
and stomach. Despite increasing number of PNET have 
been detected, PNET is still considered as a rare disease. 
There is no single study reporting the outcome on PNET 
with liver metastasis. Therefore, the best approach to 
PNET with liver metastasis is yet to be answered. 
Conclusions
Due to rarity of PNET, there was limited evidence of 
best management of patients having PNET. Balancing 
the surgical risk of pancreatectomy, active surveillance on 
PNET less than 2 cm should be considered. Laparoscopic 
pancreatic surgery is feasible in the hand of experienced 
surgeons. Further studies on optimal management of 
PNET liver metastasis should be encouraged.
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